Premium
Premium statistics

Industry-specific and extensively researched technical data (partially from exclusive partnerships).

A paid subscription is required for full access.

Revenue of Johnson & Johnson worldwide from 2011 to 2018, by segment
(in million U.S. dollars)
Revenue of Johnson & Johnson worldwide 2011-2018, by segment
The pharmaceutical segment of Johnson & Johnson was the company’s strongest segment during 2018, generating over 40 billion U.S. dollars of revenue globally. The rise of pharmaceuticals as the company’s leading segment began in 2013, when it was about even with the medical devices and diagnostics segment for the first time. Johnson & Johnson’s third pillar is the consumer health segment.

Johnson & Johnson company overview

New Jersey-based Johnson & Johnson is a global diversified healthcare company, with the pharmaceutical business becoming increasingly dominant over time. Within Johnson & Johnson’s pharmaceutical segment, oncology and immunology are the major therapeutic areas. But Johnson & Johnson also has two other strong business segments: medical devices and diagnostics, and consumer packaged goods. In fact, these segments rank J&J among the world’s top 10 medical technology companies as well as the world’s number one consumer health company.

The company’s pharmaceutical segment

Since 2013, the pharmaceutical segment showed significant growth within J&J’s segments. That the company shows particular engagement in this field is also visible by the size of its R&D pipeline which is one of the largest within the pharma industry, as of 2019. Only Novartis and Takeda showed a higher count of drugs in the pipeline. Johnson & Johnson was also ranked second worldwide based on the number of originated drugs, as of the same year. These developments are comprehensible when taking into account the company’s share of revenue which is invested into research and development. Since 2010, it has shown an almost constant increase.
Revenue of Johnson & Johnson worldwide from 2011 to 2018, by segment
(in million U.S. dollars)
Medical Devices and DiagnosticsPharmaceuticalConsumer
----
----
----
----
----
----
----
----
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in
Source

Release date

February 2019

Region

Worldwide

Survey time period

2011 to 2018

Supplementary notes

This statistic was assembled from several editions of Johnson & Johnson's annual financial report.

Revenue of Johnson & Johnson worldwide 2011-2018, by segment
The pharmaceutical segment of Johnson & Johnson was the company’s strongest segment during 2018, generating over 40 billion U.S. dollars of revenue globally. The rise of pharmaceuticals as the company’s leading segment began in 2013, when it was about even with the medical devices and diagnostics segment for the first time. Johnson & Johnson’s third pillar is the consumer health segment.

Johnson & Johnson company overview

New Jersey-based Johnson & Johnson is a global diversified healthcare company, with the pharmaceutical business becoming increasingly dominant over time. Within Johnson & Johnson’s pharmaceutical segment, oncology and immunology are the major therapeutic areas. But Johnson & Johnson also has two other strong business segments: medical devices and diagnostics, and consumer packaged goods. In fact, these segments rank J&J among the world’s top 10 medical technology companies as well as the world’s number one consumer health company.

The company’s pharmaceutical segment

Since 2013, the pharmaceutical segment showed significant growth within J&J’s segments. That the company shows particular engagement in this field is also visible by the size of its R&D pipeline which is one of the largest within the pharma industry, as of 2019. Only Novartis and Takeda showed a higher count of drugs in the pipeline. Johnson & Johnson was also ranked second worldwide based on the number of originated drugs, as of the same year. These developments are comprehensible when taking into account the company’s share of revenue which is invested into research and development. Since 2010, it has shown an almost constant increase.
Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.
Statistics on "Johnson & Johnson"
  • Global positioning
  • Revenue and income
The most important statistics
  • Segments
  • Miscellaneous
  • Forecasts
Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.